Clinical trials: Atopic Skin
Dermatitis, Contact, Dermatitis
Post-Marketing Clinical Follow-Up Trial to Evaluate the Performance and Safety of the Medical Device 047 TD Dermatitis Cream in Adults and Children With Atopic and Contact Dermatitis Symptoms Confirmed by Clinical Parameters
The study aims to evaluate and confirm the performance of 047 TD Dermatitis cream in the improvement of eczematous dermatitis and contact dermatitis, throughout a reduction in disease severity and symptoms.
- Conditions
- Dermatitis, Contact, Dermatitis, Dermatitis, Chronic, Dermatitis, Eczematous
- Trial name
- NCT07056569
- Testing
- 047_TD Dermatitis cream twice a day for 28 days
- Where
- 3 sites in Italy
- Volunteers
- 90 people
- Sponsor
- Biokosmes Srl
Atopic Dermatitis, Atopic Dermatitis Eczema
The Efficacy of NTU 101 Lactic Acid Bacteria Powder in the Adjuvant Improvement of Atopic Dermatitis Clinical Trial
This study is a randomized, double-blind, placebo-controlled, parallel-controlled trial (14 weeks in total), divided into three periods (screening, treatment, and discontinuation follow-up)
- Trial name
- NCT05719649
- Testing
- Lactic acid bacteria NTU 101
- Volunteers
- 72 people
- Sponsor
- SunWay Biotech Co., LTD.
Atopic Dermatitis
A Study to Confirm the Efficacy and Safety of Different Dupilumab Dose Regimens in Adults With Atopic Dermatitis (AD)
The primary objective of the study was to assess the ability of different Dupilumab dose regimens, administered as monotherapy, to maintain the treatment response achieved after 16 weeks of initial treatment with Dupilumab…
- Trial name
- SOLO-CONTINUE (NCT02395133)
- Testing
- Dupilumab
- Volunteers
- 422 people
- Sponsor
- Regeneron Pharmaceuticals
Dermatitis, Atopic
A Study of KY1005 in Patients With Moderate to Severe Atopic Dermatitis
The purpose of this research study is to investigate if KY1005 results in improvement of eczema when given to participants with moderate to severe disease. Side effects of KY1005 will also be explored.
- Trial name
- NCT03754309
- Testing
- KY1005
- Where
- 19 sites in Germany, Poland and 2 more
- Volunteers
- 89 people
- Sponsor
- Kymab Limited
Atopic Dermatitis, Type 1 Hypersensitivity
Allergic Disease Onset Prevention Study
This is a Phase 1b/2, randomized, double-blind, multi-center study to evaluate the safety, tolerability, and preliminary clinical efficacy of STMC-103H in neonates and infants at risk for developing allergic disease (Type 1…
- Trial name
- adored (NCT05003804)
- Testing
- STMC-103H
- Where
- 31 sites in United States, Australia and 1 more
- Volunteers
- 283 people, healthy volunteers welcome
- Sponsor
- Siolta Therapeutics, Inc.
Dermatitis, Atopic
Skin Irritation Study of GSK2894512 Cream
GSK2894512 is a novel anti-inflammatory agent that is currently under development for the topical treatment of atopic dermatitis and chronic plaque psoriasis.
- Trial name
- NCT02637206
- Testing
- GSK2894512 Cream, Vehicle Cream, Empty Patch
- Where
- Japan
- Volunteers
- 26 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Atopic Dermatitis
Steroid-Sparing Effect With Pimecrolimus in Pediatric Patients With Atopic Dermatitis
This study will investigate the steroid sparing effect of pimecrolimus cream 1% in pediatric atopic dermatitis
- Trial name
- NCT00351052
- Testing
- Pimecrolimus
- Where
- Germany
- Volunteers
- 184 people
- Sponsor
- Novartis
Atopic Dermatitis
Reconstitution With Pimecrolimus Cream 1% of Steroid-damaged Skin in Adults With Atopic Dermatitis
Topical steroid use may lead to skin deterioration and spider veins. This study will examine long-term management of atopic dermatitis (AD) over 12 months with pimecrolimus cream 1% and its effect on skin reconstitution of…
- Trial name
- NCT00367393
- Testing
- Pimecrolimus cream 1%
- Where
- Germany
- Volunteers
- 41 people
- Sponsor
- Novartis
Atopic Dermatitis
Safety and Efficacy of Pimecrolimus Cream 1% in Mild to Moderate Head and Neck Atopic Dermatitis (AD) Patients
This study is not being conducted in the United States. Patients who are intolerant of topical corticosteroids (TCS) have either experienced an adverse event resulting from the use of TCS, or require unacceptable levels of…
- Trial name
- NCT00121316
- Testing
- Pimecrolimus
- Where
- Switzerland
- Volunteers
- 200 people
- Sponsor
- Novartis
Atopic Dermatitis
A Study of Baricitinib (LY3009104) in Participants With Moderate-to-Severe Atopic Dermatitis
The purpose of this study is to evaluate the safety and effectiveness of Baricitinib in eczema.
- Trial name
- NCT02576938
- Testing
- Baricitinib, Triamcinolone (Optional)
- Where
- 13 sites in United States, Japan
- Volunteers
- 124 people
- Sponsor
- Eli Lilly and Company
Atopic Dermatitis
A Clinical Trial to Evaluate the Safety and Efficacy of a Moisturizer Body Lotion and a Lip Moisturizer in Adults of Atopic Dermatitis.
This study will test the safety and efficacy of 2 moisturizers: a body lotion and a lip moisturizer. For the moisturizer body lotion, the study aims to determine the tolerance of this product by the study population, and its…
- Trial name
- NCT04950374
- Testing
- Moisturizer Body Lotion, Lip Moisturizer
- Sponsor
- Johnson & Johnson Consumer Inc. (J&JCI)
Atopic Dermatitis
A Study to Determine the Safety, Tolerability and Efficacy of KP-413 in Subjects With Atopic Dermatitis(AD)
The purpose of this study is to assess the safety, tolerability and efficacy of KP-413 topical ointment compared with vehicle ointment in treating adult subjects with atopic dermatitis (AD).
- Trial name
- NCT00932074
- Testing
- KP-413 Ointment
- Where
- 6 sites in United States
- Volunteers
- 58 people
- Sponsor
- Kaken Pharmaceutical
Atopic Dermatitis
This Study is to Assess the Efficacy of Difamilast Ointment in Mild to Moderate Atopic Dermatitis(AD)
This is a Phase 3 Double Blind multi-center study conducted at 40 investigational sites in United States to assess the efficacy and safety of Difamilast Ointment 1% in subjects ≥2 years of age with mild to moderate atopic…
- Trial name
- NCT05608343
- Testing
- Difamilast
- Where
- 39 sites in United States
- Volunteers
- 153 people
- Sponsor
- Acrotech Biopharma Inc.
Dermatitis, Atopic
Pharmacokinetic Study of Topical GSK2894512 Cream
This study will assess the systemic exposure and pharmacokinetic parameters of GSK2894512 following twice daily topical administration of 1% and 2% cream in adult subjects with AD, and will provide information about the systemic…
- Trial name
- NCT02466152
- Testing
- GSK2894512 Topical Cream
- Where
- Canada
- Volunteers
- 11 people
- Sponsor
- GlaxoSmithKline
Atopic Dermatitis
A Study to Evaluate the Safety and Efficacy of Ruxolitinib Phosphate Cream Applied Topically to Adults With Atopic Dermatitis
The purpose of this study is to establish the efficacy of each strength of ruxolitinib cream once daily (QD) or twice daily (BID) in participants with atopic dermatitis as compared with vehicle cream BID.
- Trial name
- NCT03011892
- Testing
- Ruxolitinib 0.15% Cream QD, Ruxolitinib 0.5% Cream QD, Ruxolitinib 1.5% Cream QD
- Where
- 52 sites in United States, Canada
- Volunteers
- 307 people
- Sponsor
- Incyte Corporation
Eczema
Clinical Evaluation of a Soothing Moisturizing Lotion in Individuals With Atopic Eczema
To investigate the safety and efficacy of the moisturizing lotion in improving eczema symptoms among individuals with atopic eczema in Malaysia.
- Trial name
- NCT07463079
- Testing
- Moisturizing lotion
- Where
- Malaysia
- Volunteers
- 15 people, healthy volunteers welcome
- Sponsor
- USMARI Research & Innovation Centre
Atopic Dermatitis (AD), SCORAD Index (15-25)
In-Use Tolerance Study Under Dermatological and Pediatric Controls of Sunscreen in Children With Atopic Dermatitis
Atopic dermatitis is a chronic skin condition requiring sun protection, yet research on sunscreen effectiveness and skin tolerance in Atopic Dermatitis is limited.
- Trial name
- NCT07194408
- Testing
- Sunscreen RV4620A RP2552
- Where
- Mauritius
- Volunteers
- 22 people
- Sponsor
- Pierre Fabre Dermo Cosmetique
Atopic Dermatitis (AD)
A Study to Explore the Safety, Tolerability, Efficacy, and Pharmacokinetics of LT-002-158 Tablets in Chinese Adult Subjects With Atopic Dermatitis
This study is an Ic/II phase clinical trial conducted in Chinese subjects with moderate to severe atopic dermatitis. The phase Ic study is a randomized, open label, parallel group design, mainly evaluating the safety and…
- Trial name
- NCT06931990
- Testing
- LT-002-158 tablets
- Where
- China
- Volunteers
- 24 people
- Sponsor
- Leadingtac Pharmaceutical (Shaoxing) Co., Ltd.
Atopic Dermatitis
A Study Evaluating the Safety and Efficacy of QGE031 in Atopic Dermatitis Patients
The study will assess the safety and efficacy of QGE031 in the treatment of moderate to severe atopic dermatitis patients. In addition, QGE031 levels in the blood will be measured and the effect of QGE031 on markers in the blood…
- Trial name
- NCT01552629
- Testing
- QGE031, Cyclosporine A
- Where
- 4 sites in Austria, France and 1 more
- Volunteers
- 22 people
- Sponsor
- Novartis Pharmaceuticals
Allergy
Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Immunogenicity of QGE031 in Japanese Atopic Male Subjects
This study will evaluate the safety, tolerability, pharmacokinetics, pharmacodynamics and immunogenicity of QGE031 in Japanese atopic male subjects in order to determine the eligibility of Japanese patients in subsequent clinical…
- Trial name
- NCT01596712
- Testing
- QGE031
- Where
- Japan
- Volunteers
- 209 people, healthy volunteers welcome
- Sponsor
- Novartis Pharmaceuticals